| Depression and anxiety in Parkinson disease. S Ray, P Agarwal Clinics in geriatric medicine 36 (1), 93-104, 2019 | 87 | 2019 |
| Neurological manifestations in 404 COVID-19 patients in Washington State P Agarwal, S Ray, A Madan, B Tyson Journal of neurology 268 (3), 770-772, 2021 | 42 | 2021 |
| Management of lower urinary tract symptoms in Parkinson's disease in the neurology clinic A Madan, S Ray, D Burdick, P Agarwal International Journal of Neuroscience 127 (12), 1136-1149, 2017 | 21 | 2017 |
| Altered mental status in 71 deaths due to COVID-19 B Tyson, L Erdodi, S Ray, P Agarwal International Journal of Neuroscience 132 (6), 539-542, 2022 | 17 | 2022 |
| Optimizing Recruitment of Racial and Ethnic minority population in Clinical Trials in Parkinson’s Disease: Potential Barriers and Prospective Strategies (P4. 010) P Agarwal, S Ray, D Burdick, A Griffith, A Madan Neurology 88 (16 Supplement), 2017 | 4 | 2017 |
| A novel trial of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in Parkinson's disease (MAESTRO) A Madan, T Brown, S Ray, P Agarwal, I Roy-Faderman, D Burdick Cureus 14 (11), 2022 | 2 | 2022 |
| Effectiveness and tolerability of mirabegron and behavioral therapy in patients with Parkinson's disease and overactive bladder: a prospective, randomized, placebo-controlled … S Ray, D Burdick, P Agarwal, A Madan MOVEMENT DISORDERS 35, S474-S475, 2020 | 1 | 2020 |
| A Prospective, Randomized, Placebo-Controlled Pilot Study of Mirabegron (Myrbetriq®) and Behavioral Modification for Overactive Bladder in Parkinson Disease (908) P Agarwal, T Brown, S Ray, A Madan, I Roy-Faderman, D Burdick Neurology 94 (15 Supplement), 2020 | 1 | 2020 |
| Strategizing Clinical Trial Recruitment in the Digital Age (P1. 9-072) P Agarwal, S Ray, D Burdick Neurology 92 (15_supplement), P1. 9-072, 2019 | 1 | 2019 |
| Clinical Research Participation: Trials And Tribulations of The Limited English Proficiency Patient Volunteer in Parkinson’s Disease Clinical Trials.(P5. 071) P Agarwal, S Ray, D Burdick, A Griffith Neurology 90 (15_supplement), P5. 071, 2018 | 1 | 2018 |
| Improving racial and ethnic diversity in Parkinson's disease clinical trials S Ray, A Madan, D Burdick, A Griffith, P Agarwal MOVEMENT DISORDERS 32, 2017 | 1 | 2017 |
| Don't miss the diagnosis: neurological manifestations as presenting features of COVID-19 A Madan, P Agarwal, S Ray, B Tyson Clinical Medicine 23 (Suppl 6), 7-7, 2023 | | 2023 |
| A Study on the Correlations Between Comorbid Disease Conditions and Central and Peripheral Neurological Manifestations of COVID-19 A Vaish, S Ray, B Tyson Cureus 14 (10), 2022 | | 2022 |
| Neurological Manifestations, Comorbidities, and Outcomes of COVID-19 in Parkinson’s Disease Patients (5184) U Sharma, A Madan, B Tyson, S Ray, P Agarwal Neurology 96 (15 Supplement), 2021 | | 2021 |
| A Report on the Association of Medical Comorbidities and Neurologic Manifestations in 484 Patients with COVID-19.(5156) A Vaish, B Tyson, S Ray Neurology 96 (15_supplement), 5156, 2021 | | 2021 |
| Central and Peripheral neurological manifestations of COVID-19 in a cohort of patients with Parkinson's disease A Vaish, B Tyson, S Ray Movement Disorders, S285-S285, 2021 | | 2021 |
| Effectiveness and Tolerability of Mirabegron and The Impact of Pelvic Floor Exercise Based Behavioral Therapy in Patients with Parkinson Disease and Overactive Bladder … S Ray International Congress of Parkinson’s Disease and Movement Disorders …, 2020 | | 2020 |
| A Prospective, Randomized, Placebo-Controlled Pilot Study of Mirabegron (Myrbetriq®) and Behavioral Modification for Overactive Bladder in Parkinson Disease. S Ray. 72 nd Annual American Academy of Neurology Meeting, 2020 | | 2020 |
| Neurological manifestations in 404 COVID-19 patients in Washington state. BT Pinky Agarwal, Sudeshna Ray, Arina Madan 10.1007/s00415-020-10087-z JOON-D-20-01577R1, 2020 | | 2020 |
| Using Social Media for Parkinson's Disease Clinical Trial Recruitment S Ray, DJ Burdick, P Agarwal MOVEMENT DISORDERS 34, S12-S13, 2019 | | 2019 |
